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Abstract 
Based on a case study of a clinical stem cell intervention (CSCI) centre in Chennai in India, 
this paper explores distinct entrepreneurial strategies for the promotion of unrecognized 
clinical stem cell application in India. It shows that the Centre - an Indo-Japanese joint-
venture – is able to promote the CSCI due to its central position in a network relationship, its 
possession of specialized skills and knowledge, and because of its ability to maneuver, 
identify and utilize the latent value of other actors in the network. We have deliberated on the 
developmental history of the making and remaking of regulation, and the shift in the way 
clinical stem cell application providers’ function – from institutional embedment to strategic 
linking through collaborative networks. We ask why and how unauthorized clinical 
applications are sustained and promoted in India. We conclude that this is possible as a result 
of a number of factors: jurisdictional ambiguity, institutional inability, issues concerning the 
legally enforceability of the relevant guidelines, the complexity of the collaborative-network 
structure that facilitates the circumvention of the regulation, and the non-functioning of apex 
level committees. 
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Introduction 
Over one and half decades, notwithstanding its modest global standing in science and 
technology innovation, India has emerged as a major player in the stem cell sector expressed 
in research activities, including the creation of embryonic stem cell lines, a steady flow of 
patients in search of stem cell treatment, an increasing number of clinics and hospitals, and 
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the publication of scientific papers (Inamdar et. al. 2009; Sharma 2009; Patra & Sleeboom-
Faulkner 2010; Tiwari and Desai 2011; Bharadwaj 2012; Tiwari & Raman 2014). Both 
government and private institutions and industries have invested heavily in stem cell research, 
its clinical application and the production of cell-based therapeutic products (Sharma 2006; 
Bharadwaj 2014). While these efforts are highlighted nationally and internationally (Salter 
2008; Lander et.al. 2008, Tiwari & Raman 2014), significant concerns have been raised since 
the early 2000s over unproven stem cell treatments being offered at government and private 
clinics, hospitals and companies with apparently little regulatory oversight (Jayaraman 2005; 
Srinivasan 2006; Pandya 2008; Patra & Sleeboom-Faulkner 2009, 2011; Tiwari & Raman 
2014). These therapies are understood to be lacking in preclinical evidence of their efficacy 
and safety (Cohen &Cohen 2010).  Companies and institutions providing stem cell 
intervention offer very little or no information about the terms of reference on the medical 
conditions that necessitated the intake of patients, the scope of pre-clinical studies, whether 
informed consent has been provided by the patients and whether these treatments have duly 
been approved by an authorized regulatory body (Cohen &Cohen 2010; Sleeboom-Faulkner 
2010; Tiwari & Raman 2014). 
 
In 2002, the Indian Council of Medical Research (ICMR), institutionally located under the 
health ministry, announced a policy that permitted therapeutic cloning and encouraged stem 
cell research. But, the previous year the Department of Biotechnology (DBT), under the 
science ministry, had also issued guidelines, and some clinics had exploited the difference 
between the two sets of guidelines, starting clinical treatments (Jayaraman 2005). 
Subsequently, with an increasing number of funding applications to the ICMR and the DBT, 
media reporting of unethical practices in biomedical research, and India’s growing thrust on 
stem cell research, the DBT and ICMR in 2005 decided to jointly devise guidelines, which 
were released as the Guidelines for Stem Cell Research and Therapy in November 2007 
(DBT-ICMR 2007). The guidelines permit research pertaining to adult and umbilical cord 
blood stem cells if approved by Institutional Ethics Committees. 
One would have expected that with the introduction of the 2007 guidelines, the provision of 
what were regarded as ‘unrecognized’ stem cell intervention to be unavailable. The 
guidelines did have some influence over government-funded hospitals (e.g. AIIMS, New 
Delhi) as adherence to guidelines was linked to funding from the central ministries (Tiwari & 
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Raman 2014, Tiwari & Desai 2011, Patra & Sleeboom-Faulkner 2011). However, guidelines 
had little impact on private clinics, hospitals and companies, which constituted a large part of 
stem cell related activities in India. Reports about the availability of unrecognized stem cell 
intervention at increasing numbers of private clinics, hospitals and companies surfaced in 
media reports, internet blogs, science magazines and medical ethics journals (Kahn 2007; 
Pandya 2008; Salter 2008; Bharadwaj and Glasner 2009; Khullar 2009; Patra & Sleeboom-
Faulkner 2009; Cohen and Cohen 2010; Dhar 2010; Jain 2010). Some critics argued that the 
2007 guidelines lacked legislative force (Pandya 2008, Patra & Sleeboom-Faulkner 2011, 
Tiwari and Raman 2014).  
The cumulative consequence of these reports, coupled with the aim to project India as a 
responsible player in global stem cell science, forced the policy and regulatory bodies in 
India, such as the Indian Council of Medical Research (ICMR) and the Department of 
Biotechnology (DBT) to revise the regulatory guidelines formulated in 2007. Starting in 2010, 
the revised stem cell guidelines were prepared in December 2013. After several rounds of 
public consultations in different parts of the country and deliberations by expert committees, 
the revised ‘Guidelines for Stem Cell Research’ (2013) was published. The new guidelines 
omitted the term ‘stem cell therapy’ from its title page, and announced a stricter oversight 
through a more active National Apex Committee (NAC) (Gupta &Gandhi 2014). In its 
Foreword, the document declared that the revised guidelines would “reflect new scientific 
and clinical findings that have significantly changed the scope of stem cell research and 
possible translation”. While discussing the changes in the mechanism for oversight, it said 
“an additional layer of oversight, besides the Institutional Ethics Committee (IEC), in the 
form of Institutional Committee for Stem Cell Research (IC-SCR) and National Apex 
Committee for Stem Cell Research and Therapy (NAC-SCRT) has been introduced. This 
mechanism of additional review has been accepted by the scientific community in the country 
and the required NAC-SCRT has become operational. The role and functioning of these 
committees is being streamlined” (ICMR-DBT 2013). This meant that no stem cell 
intervention would be considered for certification; only clinical stem cell trials. The refusal to 
address “stem cell therapy” in the regulation thus marginalized the lion share of India’s 
providers of stem cell intervention. 
The above discussion describes the linear development of stem cell guidelines in India. What 
we have found, however, is that while the development of guidelines as a response to 
controversy seemed to be straightforward, the question of jurisdictional authority over their 
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implementation has been more complicated (Tiwari & Raman 2014). The question arises here, 
whether this jurisdictional authority or lack of it has been the reason for the unceasing 
availability of unproven stem cell treatment at an increasing number of private clinics, 
hospitals and companies at many locations in India.  It is important to note here that neither 
the ICMR nor the DBT has a legislative remit over medical research in India. The ICMR is 
the apex body in India for the formulation, coordination and promotion of biomedical 
research, and DBT is a department under the Ministry of Science and Technology responsible 
for administrating development and commercialization in the field of modern biology and 
biotechnology in India. None of them have a remit over the activities taking place outside 
government-funded R&D (research and development) programs. 
The Drug Controller General India (DCGI) under the gamut of the Central Drug Standard 
Organization (CDSCO) is responsible for the regulatory control over the import of drugs and 
theapproval of new drugs and clinical trials. It is frequently characterized as the “Indian 
FDA” and it would have been the obvious candidate to extend its remit to stem cells. In the 
early days, it appeared that the DCGI was uncertain about the reach of its powers which may 
be due to the fact that it is only nominally similar to the FDA, with a remit primarily related 
to drug approvals (SundarRajan 2007). In their study, Tiwari and Raman (2014) held that the 
DCGI had no experts of its own who were able to evaluate stem cell proposals, and suggested 
that ‘a fundamental jurisdictional ambiguity with even the relevant agency unsure of what 
falls under its regulatory scope’. 
In brief, the linear trajectory of development of stem cell guidelines in India was an outcome 
of attempts to better govern the reported malpractices on one hand and to make India ready 
for the global stage as a competitive and collaborative partner in new biotechnologies, on the 
other. India has definitely moved in a direction, from a ‘governance vacuum’ to a ‘thick 
regulatory framework’. The growing availability of unapproved stem cell intervention mainly 
at private clinics, corporate hospitals and companies attests to the fact that implementation of 
these guidelines on the ground is feeble. It would be easy to explain this as ‘institutional 
failure’ or ‘institutional ambiguity’ as demonstrated in the case of the non-functionality on 
the part of NAC-SCRT oversight, and the uncertainty of the DCGI and about its own 
regulatory scope and role. 
As the discussion above indicates, social science literature has tiered to explain why 
unrecognized stem cell interventions (USCI) are provided in India since guidelines were put 
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in place in 2007, and some do this in relation to the existence of a bioethical or governance 
vacuum (Salter 2008;  Sleeboom-Faulkner 2010; Cohen &Cohen 2010), institutional 
embedding (Patra & Sleeboom-Faulkner 2011) and jurisdictional ambiguity (Tiwari & 
Raman 2014), whileothers highlight making profit, acquiring glory, advancing experimental 
medicine (Kiatpongsan & Sipp, 2008), and ‘filling the gap’ between demand for health-care 
and supply of treatment. While understanding why provision is continued, it is important that 
social scientists examine how stem cell intervention activities continue to be carried out in 
India. Knowing how providers operate requires knowledge that pertains to institutional 
arrangements and strategies to circumvent regulatory safety nets. This we attempt to explain 
through the notion of ‘bionetworking’, which refers to social entrepreneurial network 
activities involving biomedical research and healthcare institution that respond to the health 
needs of the patients commercial demands of therapy providers (Patra & Sleeboom-Faulkner 
2009). A bionetwork consists of a plurality of actors engaged in ‘biotechnical ventures’ 
(Waldby& Mitchell, 2007) working across geographical spaces, regulatory regimes and 
social institutions. It relates to the entrepreneurial aspects of biomedicine, and the strategic 
use of the differences and similarities in the provision of healthcare, levels of wealth, 
standards of scientific development, research regulatory regimes and their implementation 
and relative values of collaborators involved (Sleeboom-Faulkner 2016, Patra & Sleeboom-
Faulkner 2011). 
In this article, then, we are more concerned about the strategies of these institutions (the how) 
adopted to continue the provision of stem cell intervention.  This approach explicates the 
institutional arrangements and attitudes/approaches to stem cell regulation. It may also shed 
light on a related, yet, hypothetical question. If ethical oversight is tightened and soft 
guidelines become hard-law with punitive powers, can we expect the demise of unapproved 
stem cell intervention in India? The implementation of Pre-Conception and Pre-Natal 
Diagnostic Techniques (PCPNDT) Act (1994), an Act of the Parliament of India enacted to 
stop female feticides and to arrest the declining sex ratio in India shows that ‘hard law’ is not 
necessarily effective. Two decades after the enactment of the PCPNDT Act, the law cannot 
control all clinics that use ultrasound for sex determination and a host of other purposes, 
including detection of genetic abnormalities in the foetus (Garg and Nath, 2008; Bhalla 2015). 
Without going into great detail about why unapproved stem cell interventions are available in 
India, we will, discuss how some private clinics, corporate hospitals and companies promote 
and continue practicing such treatments. What we suggest is that the changing regulatory 
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situation in India is commensurate with a shift in the structural form of arrangements 
promoted by treatment providers themselves. As will become clear we see a shift in the 
institutional embedding (Patra & Sleeboom-Faulkner 2010, 2013) of various kinds of 
practitioners (e.g. public, private and independent), and an increase in collaborative networks 
between actors with diverse intent and expertise. As discusses below, these activities 
encompass interactions with a wide variety of stakeholders and institutions, ranging from 
political agencies, to corporate sponsors and subsidiary companies, to patient groups, local 
hospitals, universities, and the media (Sleeboom-Faulkner 2014).  
 
Methodology 
This article is based on data gathered through both primary and secondary sources. Empirical 
data were collected by both authors over 10 months from 2010 to 2014. In 2010 11, the first 
author carried out the fieldwork in India for 3 months and the second author in Japan for 3 
months. In 2013 14, the first author carried out the fieldwork for 4 months, between 
September 2013 and January 2014. We have visited multiple sites across India and some in 
Japan that include: 4 stem cell companies, 5 stem cell research institutes, and 8 hospitals and 
clinics where we interviewed patients/care givers (12), medical doctors (7), stem cell 
researcher (14), scientists (7), treatment providers (6), bioethicist (5), institutional review 
board members (3), venture capitalist (5), and patient organizations (3). The institutes, centers, 
stem cell banks and hospitals visited include the Nichi-In Centre for Regenerative Medicine 
(NCRM), Jeevan Stem Cell Bank, and Lifelong Institute for Regenerative Medicine (LIRM) 
in Chennai, Stempeutics Research Pvt. Ltd., International Stem Cell Services Limited (ISSL), 
Manipal Institute for Regenerative Medicine (MIRM) in Bangalore, ReeLabs and NeuroGen 
in Mumbai, Chaitanya Stem Cell Centre and LifeCell in Pune, CryoBank in Gurgaon, Indian 
Institute of Medical Research, Udaan Centre and All India Institute for Medical Sciences 
(AIIMS) in New Delhi, Tran-Scell Biologics Ltd in Hyderabad and Kalinga Institute for 
Industrial Technology (KIIT) in Bhubaneswar in India. In Japan, besides interviews with key 
persons in IJRM, secondary source materials were collected, including materials from web 
pages of the above-mentioned institutes, newspaper articles, conference materials, official 
documents related to stem cell research and healthcare governance published by government 
bodies and articles and research papers published in national and international journals on 
stem cell in India. We use pseudonyms for the names of interviewees, and for institutions, 
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hospitals and clinics, when requests were made. However, the names of individuals or centres 
were used where they were already used in media reports or were quoted in secondary 
sources. 
 
The shift in provision of unapproved stem cell application provided by clinics in India: 
from specific institutional embedding to network-based collaboration 
As elaborated above, over the last 15 years there have been changes in the regulatory 
frameworks, healthcare policy, and techno-science practices regarding regenerative medicine, 
in India. In the initial phase (2005 - 2010), unapproved stem cell applications providers 
operating in private, public, and independent sectors formed diverse institutional contexts for 
the promotion of stem cell research and patient recruitment. State-of-the-art physical 
infrastructure and cutting-edge medical technology required heavy private investments, 
which were set off by high profits from high user fees, affordable to only a few Indian 
patients and a growing number of foreign patients. Competition to attract potential patient 
groups and a solitary focus on clinical application did not inspire private practitioners to look 
for large-scale collaborative networks. 
After 2010, attempts to revise regulatory frameworks at the national level, new developments 
in the field of stem cell science and the government’s emphasis on public- private 
partnership (PPP) in biotechnology encouraged actors such as stem cell scientists, companies, 
medical doctors, patients and their caregivers to come together to collectively address 
emerging challenges. For example, the growing interest in iPS cells, encouraging 
breakthroughs in preclinical studies using mesenchymal stem cells and Wharton jelly, and the 
popularization of umbilical cord blood and tissue banking necessitated multi-center and 
multi-actor collaborations. The DBT, in 2012, set up a ‘not-for-profit-company’ called 
Biotechnology Industry Research Assistance Council (BIRAC) as an interface agency, 
serving as a single window for the emerging biotech industry (DBT webpage 2014). These 
factors have encouraged actors such as stem cell research institutes, corporate hospitals and 
doctors to collaborate and create platforms to capitalize on relative expertise. Public and 
private centers and individual practitioners that had traditionally operated through their 
respective institutional embedding had either to create such collaborative platforms or to 
close their practice. Here, briefly, we present the contexts and motivation of scientists based 
in the public, private and independent sectors had for providing therapy ,and how they have 
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changed their set-ups over the last decade. We do this by giving one example from each 
category.  
Public sector: Public sector healthcare institutions involved in stem cell research and 
treatment receive their funding from the state. These institutions have traditionally regarded 
stem cell provision as a high-end healthcare service with humanitarian value that has the 
potential to transform the economic and health care needs of the nation. They by and large 
adhered to the official policies and guidelines formulated by the state and were relatively 
cautious and conservative with regards to scientific innovation. Compared to private-sector 
centers, public institutions and centers were also slow to enter into collaborative research and 
development activities across local and global spheres. We exemplify this using the case of 
the All India Institute of Medical Sciences (AIIMS), which is a premier medical institution in 
India, based in New Delhi. It receives substantial public funding and is in the forefront of 
medical research, including stem cell science. In the early 2000s, AIIMS claimed to have 
providing controversial experimental stem cell therapy, which was reported in 2005 in a 
leading English daily The Times of India, where the then director of AIIMS, Dr. P. 
Venugopal reported as saying: 
[We are] finally in a position to report the results of our work. Starting in February 
2003, 35 patients with end-stage cardiac disease had been given stem cell treatment 
through a technique developed at the institute. They had been monitored over six-
month intervals and the majority had improved (Srinivasan 2006).  
This ESCT took place during a time when the first ICMRDBT guidelines on stem cell 
research and treatment were in preparation. Vasantha Muthuswamy, who was then in-charge 
of developing ICMR ethical guidelines for stem cell research and therapy, expressed her 
helplessness, saying, “we are only a block away from AIIMS and we did not know this was 
happening there” (cited in Jayaraman 2005). Eventually, AIIMS stopped a multi-centric stem 
cell trial project, ‘due to lack of desired result’ and a report published in 2011 highlighted 
how NAC (the national apex committee) was critical of Drug Controller General of India’s 
(DCGI) approval of a joint clinical trial proposed by AIIMS in collaboration with a private 
company, Stempeutics Research Private Limited (Singh 2011). By contrast, AIIMS currently 
has a dedicated stem cell research facility for basic stem cell research and therapy provisions 
limited only to randomized clinical trials. This reflects how AIIMS, a leading public hospital 
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and medical institute in India, had to change its position and activities relating to stem cell 
research and treatment owing to regulatory and policy changes. 
 
Private sector: The private sector represents a myriad of healthcare institutions that receive 
funding supports from varied sources such as private firms, pharmaceutical companies and 
venture capital companies. The infrastructural facilities related to private sector stem cell 
research and therapy provision developed rapidly in India and many private sector hospitals 
have opened stem cell research wings that serve as a cover for commercial therapeutic service 
or are linked with larger client networks (Patra & Sleeboom-Faulkner 2009). Others have 
developed facilities in anticipation of a growing flow of hopeful patients from the West in 
search of therapies that are not ‘standard’ in their own country. They also targeted the upper-
class wealthy patient group in India, which was rapidly growing. The driving forces behind 
the private sector’s heavy investment in stem cell research and therapy enterprise are 
manifold. Apart from profit-making, the aspiration to play a leadership role in the cutting-
edge technology in India through large-scale collaborative research and development across 
locations plays an important role, and makes use of emerging patient flows in search of 
experimental stem cell therapy. The tale of Stemtech Research Private Limited (pseudonym), 
a stem cell-based product development company based in Bangalore, is a case in point that 
explicates how a private sector company transformed itself in last decade. In its initial period 
of existence, between 2006 and 2008, it mainly provided stem cell treatment for spinal cord 
injury and some neurological disorders. It was involved in cleaning, processing, and 
expanding the stem cells at its own laboratory facility in Bangalore and worked closely with a 
hospital group and a few corporate hospitals in and around the city for patient recruitment 
and clinical translation. But, post-2008, due to the changing regulatory scenario in India and 
Stemtech’s own decision to focus more on research and product development, it stopped 
providing ESCT. It took proactive steps to work closely with a sister institute called Nagpal 
Institute of Regenerative Medicine (NIRM) to create human resources, organize funding 
through a joint venture with a major Indian pharmaceutical company, collaborate with 
contract research organizations (CROs) for clinical trials and with an engineering company 
for stem cell-based medical device product development. It also cultivated formal and 
informal understandings with top-notch research institutes for the exchange of knowledge, 
technology, and biomaterials. It was successful in getting public funding for basic research, 
such as from DBT through the Small Business Innovation Research Initiative for Public 
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Private Partnership (SIBRI) and Biotechnology Industry Research Assistance Council 
(BIRAC) programs. Stemtech has an overseas branch in Malaysia where it is working with 
private and public institutions for stem cell research. From a relatively independent and self-
reliant company in 2006 08, it has changed into a diversified and collaborative network.  
Independent sector: Practitioners providing experimental stem cell therapies on an individual 
basis, and outside the purview of both public and private sectors view regenerative medicine 
as an opportunity for earning money, experience, and fame. They targeted a growing number 
of middle-class patients searching for better health care outside of the public health care 
system. Due to fear of reputational risk, threat to monopoly over technological know-how, 
and apprehensive of regulatory oversight, independent practitioners were operating within a 
limited scope. They were particularly averse to collaborative exercises. These different 
institutional sectors had developed varying strategies of dealing with ESCTs, which had 
generated new discursive dialects of bioethics (Patra & Sleeboom-Faulkner 2009). Dr. 
Prakash (pseudonym) is a case in point. Dr. Prakash is a medical doctor and biochemistry 
expert based at a leading publicly funded medical-college-cum-hospital in the city of Cuttack 
in Odisha State. Dr. Prakash claims to provide stem cell treatment using autologous bone 
marrow for medical conditions such as diabetic foot ulcer and Duchenne’s muscular 
dystrophy (DMD). Dr. Prakash has set up a private clinic for providing stem cell treatment, 
after the local Institutional Review Board of the public sector medical-college-cum-hospital 
to which he is affiliated did not grant him permission for clinical application. The college did, 
however, approve of him carrying out laboratory research on stem cells. Dr. Prakash 
explains:  
Since ours is a government hospital, the committee is very strict about 
implementation of ICMR guidelines. They cannot approve my study for 
clinical trials within this hospital, even though they know that what I am doing 
is medically and ethically correct. But they are waiting for other front-line 
hospitals like AIIMS to practice these therapies first. Perhaps then they will 
say yes. Once it is practiced at a big place, then they will have no problem in 
approving me. This made me provide this treatment out of this medical college 
purview (Interview, Dr. Prakash, 17.03.2009).  
Thus, due to the government hospital’s requirement to follow ICMR guidelines, Dr. Prakash 
decided to offer stem cell treatment independently in a private clinic. Although not 
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particularly lucrative, the practice becomes a testing ground for the research he does at the 
college. This was the situation prior to 2008. Dr. Prakash still continues his practice outside 
of the public hospital. Recently, Dr. Prakash was invited to a discussion platform to explore 
the possibilities for setting up a joint venture with Pluri-Scell Biologics – a Hyderabad based 
stem cell bank and processing center, JIIT University’s Biotechnology Department, and 
Mangala Institute of Medical Sciences (MIMS) hospital in Bhubaneswar. The negotiation 
discussed the use of the expertise of Dr. Prakash to attract patients from his medical college 
and MIMS hospital as potential clients for stem cell treatment (Interview 1st author, 
23.11.2013). This reflects the scope for individual actors to create new possibilities by 
combining resources from various origins. 
These three cases highlight the influence of changing national regulatory guidelines on the 
functioning of actors and institutions based in varied institutional set-ups. The private 
company, Stemtech, displays maximum flexibility in its ability to change its mode of 
operation, and it has created strategic links for dealing with challenges in the spheres of 
regulatory capacity building, technological innovation, and resource generation. AIIMS, a 
publicly funded institution, demonstrate a sense of restraint regarding stem cell 
experimentation, with limited scope for collaborative activities. Individual practitioners, such 
as Dr. Prakash, have the leeway to focus on both consolidating experimental operations and 
exploring the possibility of collaboration with larger networks.  
The following is a case study of a center named IJRM, the focus of this paper, which 
elucidates the shift in the provision of clinical stem cell intervention in India from 
embedment in particular (private, public, independent) institutions to collaborative 
enterprises. It is important to emphasize here that it is not our intention to portray this case 
study as representative for the state of affairs of stem cell research and clinical intervention in 
India. Nevertheless, IJRM in India, as we shall see, has an important exemplary function as 
one of the leading centers in India in stem cell research and treatment, explicates strategic 
maneuvering skills through a globalised bionetwork. It negotiates regulatory requirements in 
various geographies on the one hand, and encourages the expansion of therapy business 
through diversification, decentralization and network-building by using strategic linking, on 
the other.  
The India-Japan Centre for Regenerative Medicine – a case of bionetworking 
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The case of India-Japan Centre for Regenerative Medicine (IJRM), an Indo-Japanese joint 
venture based in Chennai, reflects India’s regulatory transition. It also exemplifies the shift 
from institutional embedding to an entrepreneurial network based collaborative structure that 
conditions the abilities of stakeholders to sustain their work successfully and promote 
experimental therapy. IJRM shows how central to strategic linking and value realization in 
biomedical science are the ways in which exchanges are positioned in strategic networks 
shaped through socio-economic, political-legal and cultural factors, or ‘bionetworking’ (Patra 
& Sleeboom-Faulkner 2009, Sleeboom-Faulkner 2011), also involving a myriad of non-
scientific activities, including networking, lobbying, managing, trading, and collaborative to 
produce science. These activities encompass interactions with a wide variety of stakeholders 
and institutions, ranging from political agencies, corporate sponsors and subsidiary 
companies to patient groups, local hospitals, universities and the media (Sleeboom-Faulkner 
2016). IJRM’s centrality in a collaborative network structure exhibits its capacity for 
maneuvering across local and national boundaries, understanding the increased complexity of 
clinical stem cell intervention in India.  
IJRM carries out research, training, and clinical applications-protocol development in 
regenerative medicine, with an emphasis on stem cells, progenitor cells, and autologous adult 
cells with regenerative capability. IJRM claims to possess the technology for the processing, 
expansion, and preservation of clinical grade stem cells, precursor cells as well as mature 
cells (IJRM webpage 2014). Initiated in 2004, IJRM in one decade has gradually moved from 
a relatively secluded and small-scale entity to a medium-sized registered joint venture 
company with a well-connected network structure linking multiple partners in the promotion 
of stem cell treatment in India. IJRM, being a center involved in cutting-edge science, has 
signed academic and research collaborations with universities and research institutes in India 
to promote basic research or academic training in stem cell science. In India, it has signed a 
memorandum of understanding (MoU) with two universities in Andhra Pradesh for stem cell 
research. It has also started a web-based training program in regenerative medicine in 
collaboration with the TPRM (Training Programme in Regenerative Medicine) affiliated to a 
university in Canada. These kinds of collaborative academic links provide recognition and 
academic exposure, and help maintain global linkages through faculty exchanges and work 
exposure of young researchers at IJRM. The collaborating centers in India, in turn, get access 
to advanced stem cell technology developed in Japan, which enables them to work with 
‘world-class’ scientists. The vice-chancellor of a collaborating university in India, in a 
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workshop organized by IJRM, stated that their collaboration is not only promoting research in 
the advanced life sciences, but also aims to yield solutions to the emerging health needs of 
the people of India: 
We are proud of our tie-up with IJRM that provides us with a direct link to 
advanced life science laboratories in Japan. The PPP-mode (public-private 
partnership) is going to define the future. It is the mutual trust, sharing and 
benefit that are going to take us further. It is going to be driven by knowledge 
and technology. We cannot limit our objectives merely to academic links, it 
has to go further and be meaningful for human welfare and useful to many 
people who are suffering from innumerable number of diseases… We see this 
endeavor as a need-based and practical one (Presentation IJRM workshop, 
Chennai, November 19, 2013). 
This statement suggests the various motivations of actors in the collaborative network. 
Collaborators utilize the relative value and different expertise held by each of them, while 
pursuing their own ends. The main mechanism of steering the network lies in the relative 
centrality of a hub. 
‘Relative centrality’ and ‘strategic linking’  
The IJRM promotes clinical stem cell interventions through its central position in a network 
relationship, the possession of specialized skills and knowledge, and the ability to identify 
and utilize the value of actors in the network. Characterizations of such managerial relations 
can be found in business studies using various models, including, the ‘hub-and-spoke model’ 
and ‘business cluster.’ Hubs are described as special nodes located in the network in such a 
way as to facilitate connectivity between interacting places, and they are considered as a 
catalyst for agglomeration and scale economies (O’Kelly 1998); business clusters are 
described as geographic concentrations of interconnected actors in a particular field, who 
compete but also cooperate (Porter 2000). We argue that these models are inadequate to 
explicate the dynamic relationships between actor-stakeholders in promoting clinical stem 
cell interventions. Important to the development of network relations between actors is not 
just their interdependency and relative positioning, but also the modes of strategic linking and 




The actors’ differential positioning within the dynamic of a stem cell network has important 
impact on the flow of resources in terms of knowledge, capacity, technology and services. 
One critical factor in network positioning is ‘relative centrality,’ denoting the crucial role that 
one of the actors in the network plays in uniting and mobilizing other actors in the network. 
This centrally positioned actor’s role is akin to a ‘hub.’ The hub, as the lead actor, has the 
ability to access, apply, appropriate, and control the resources of a network through direct as 
well as indirect links. Another critical factor is ‘diversity.’ The hub, by virtue of its central 
positioning and ability to maneuver, can tap the differential value or resources of the specific 
actors in the network. Presumed mutual benefit for all participating actor-stakeholders 
contributes to the stability and growth of the enterprise. A third aspect is the ‘relationality’ of 
the network. Minor actors (or ‘spokes’) can only be part of the network if they are hubs (lead 
actor) in their own networks.  
Crucial, however, is the way in which a distinct transnational network employs strategic 
linking and scaling tactics to pursue business success by means of ‘relative centrality,’ which 
is composed of three components: goal setting, strategic exposure, and the strategic linking of 
meaningful spaces. We explain how this network structure based on the notion of ‘centrality’ 
works by strategically linking and exposing the activities of certain actors when opportune.  
Strategic linking through goal setting 
The hub mobilizes and steers the expertise and talents of participating actors to achieve 
specific goals in the field of ESCT. Since 2005, IJRM has spread its activities in length and 
breadth and it has entered into mutual understandings with a broad spectrum of actors across 
local, national, and global boundaries. By virtue of its position in the network and ability to 
make use of the relative strengths of each actor, IJRM is adept at streamlining its diverse 
motivations towards an anticipated aim. For example, it has close collaborative research links 
with university hospitals, companies, and funding bodies in Japan, India, Malaysia, and 
elsewhere in the world. IJRM’s link with Japanese companies and institutes help it to receive 
wider acceptance and reputation in India, while ensuring a steady flow of innovative 
technology, research training, and funding for research and development in India. The 
collaborating companies and institutes of Japan, in turn, gain access to a wider patient 
population, revenue through technology transfer, and well-trained inexpensive expertise. A 
research scientist attached to IJRM explained the company strategy: 
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Ours is a unique centre. Here you find all stem cell solutions under one roof. 
With our collaborative links with Japanese universities and companies, we 
manage to get access to world-class technology and knowledge. Then we have 
entered into Memorandum of Understandings with universities in Canada and 
India for higher research and training in stem cell science. We are the first 
institute in India to start providing Autologous NK cell-based immune cell 
therapy for cancer, and it provides a platform for collaboration between like-
minded scientists and clinicians in all specialties of medicine where there is a 
potential for regenerative medicine-based solutions. We also collaborate with 
cord blood banks. It is a center for complete solution (Interview, Dr. DS, 
Chennai, October 21, 2013). 
The IJRM has recently entered into collaboration with the well-known private sector chain 
Apex Specialty Hospital in Chennai for the provision of Natural Killer (NK) cell-based 
autologous immune enhancement therapy (AIET). AIET is used to treat patients with acute 
lymphoblastic leukemia, a kind of blood cancer (IJRM webpage, 2014). IJRM provides 
technological support in the form of immune cell therapy, while Apex provides medical 
facilities and patient care. IJRM, in fact, has collaborations with over 60 small- to medium-
level clinics and hospitals, to which it provides stem cell-based technological services, 
including cell processing and cell expansion, and where the hospitals deliver the treatment.  
Some of the actors, especially those involved in stem cell research and clinical applications, 
emphasize the importance of the publication of their study results, as it provides the 
enterprise with legitimacy. Thus, to legitimize its practices and to promote its name, IJRM 
has been publishing a journal called the Journal of Stem Cell Research and Therapy since 
2009. Although it is not peer reviewed, it provides the scope and opportunity for researchers 
at IJRM and its collaborating partners to showcase a selection of their studies and clinical 
data. A clinician collaborating with IJRM to research and clinically apply corneal lymbal 
stem cells explains the importance of publishing: 
My association with IJRM not only helps me to work in a high-throughput 
scientific area of stem cells, but also gives me a chance to showcase my 
research in a reputed science journal. This is crucial. It helps in getting 
academic acceptance (Interview, CS-3, November 23, 2013). 
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The strategic linking of clinics, companies and researchers that have access to new cell 
technologies and biomaterials facilitates the creation a platform for the promotion of 
experimental stem cell therapy, showcasing research through publications and putting 
compelling case histories of patients on websites. In practice, it is impossible to draw a line 
between the fundamental research, clinical translation, and entrepreneurial activities of the 
network (Sleeboom-Faulkner 2016). 
 
Strategic exposure 
The entrepreneurial stem cell network enterprise strategically exposes certain aspects of its 
collaborative network and activities more than others. Thus, IJRM as a hub has the overview 
and therefore the unique capacity to recognize the specific values of the diverse actors in the 
network. It creates a situation of dependency and mutuality by enhancing their competencies 
and by helping them to channel their potential towards the goal of promoting the stem cell 
treatment enterprise. The hub, in this case IJRM, can skillfully manipulate, mobilize, and 
make use of the resources that lie within the reach of other participating actors in the network. 
In doing so, it may decide to display the potentials and value of specific actors required in a 
specific context of entrepreneurial negotiation, scientific venture, and ethical consultation. It 
becomes the prerogative of the principal actor, based in the hub, to decide which aspects of a 
collaborating partner’s expertise can be made visible to an interested client and which not. As 
a research scientist working for IJRM explained: 
Specialized hospitals in Chennai have a good reputation in India for providing 
world-class treatment options for reasonably low prices compared to other 
cities in India. There are many who want to provide the best therapeutic 
options to their needy patients. It is their objective. We just help them in 
achieving that with the best technology and know-how that we have. We 
provide them with processed and expanded cells as per their requirement, for 
experimental use. It is a mutually beneficial thing (Interview, RS-3, November 
23, 2013). 
The research scientist recognizes the important value that local clinics hold for the enterprise, 
but this recognition is not openly expressed. When asked why IJRM does not showcase the 
role of the local clinics or hospitals on the website, the scientist said:  
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We don’t need to tell everyone which clinic or hospital is our local 
collaborator. It is perhaps not necessary for everyone to know. Ultimately, the 
patient who would receive the treatment will come to know when he contacts 
us with detailed medical documents (Interview, RS-3, November 24, 2013).  
Although the principal actor, based in the hub, recognizes the potential and relative value of 
minor actors, it conceals their identities from outsiders and, at times, it may overplay the role 
of specific minor actor to achieve a specific goal. A well-known neurosurgeon, who owns a 
local clinic in Chennai, has close links with IJRM. Several times he has processed stem cells 
for the therapeutic use of patients suffering from neurological problem. He explained how he 
became part of the network:  
(R)ather, I was discovered by IJRM (laughing). When they came to know 
about my reputation as a good surgeon in the area, they wanted to tie up with 
me for the promotion of their stem cell service products. I was also looking for 
avenues for this wonderful thing around stem cell treatment. I got impressed 
with their claims, their links with Japanese professors and researcher. I got 
excited. It was like we were made for each other. This technology that we are 
using is very unique and the Japanese company has exclusive rights over it. 
This has a good psychological impact on our patients’ mind (Interview, C-2, 
November 21, 2013). 
These interviews reflect how the entrepreneurial network built to promote clinical stem cell 
interventions in India adopt a split strategy in which there is a task division between actors: 
actors engaged in basic research, and actors engaged in translational research, whose 
innovative and sought-after field involves practices that are ethically challenging.  
 
The strategic linking of geographical spaces and meaning 
This section explores the entrepreneurial logics shaped by techno-business practices, 
institutional forces, and material complexities through which actors negotiate scaled spaces at 
a local, national and global level. (Patra & Sleeboom-Faulkner 2011) have showed how the 
leader of a stem cell hub skillfully taps unauthorized resources by licensing innovative 
Japanese technologies to hospitals in India. He thus capitalizes on the need of Japanese 
research centers to experiment with their technologies on patients who are more easily made 
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available in India. We speak of spaces, as the geographical spaces in themselves provide a 
functional source of meaning in entrepreneurial networks. Examples are the clean and high-
tech images of Japanese technology used when branding products, transferring technology, 
recruiting patients, and negotiating regulation.  
The IJRM has strategic links in Chennai city with hospitals, such as Deepam Hospital, 
Shrushti Hospital and Sankar Nethralay and, formerly, with Lifelong Hospital. IJRM 
conducts research on corneal lymbal stem cells, corneal endothelial precursors, hepatic 
progenitors, chondrocytes and hematopoietic stem cells. It provides autologous bone marrow 
stem cell processing services, and claims to offer treatment for various illnesses. The official 
web page of IJRM explicitly declares that its stem cell treatment and other therapy services 
are based on advanced Japanese technology: 
One of our core strengths has been the possession of technology (both 
materials and methodologies) for processing, expanding, and preservation of 
clinically usable stem cells, precursor cells, as well as mature cells. We have a 
unique advantage of having biomaterial and nanotechnology-based (without 
animal protein contamination) stem cell processing and expansion technology 
through our collaboration with Japanese institutes.  
With its claim of having exclusive access to advanced Japanese technology for cell 
processing and expansion, it attracts physicians, usually based in small- to medium-level 
private hospitals. A senior physician-cum-scientist at IJRM explained: 
We have collaborative works with around 40 hospitals in India, especially in 
southern India and about 15 to 20 in Chennai city. It is not a very strong link; 
they take our support when they have a need and that is good for us. We want 
our resources to have wider use and more people to benefit. We want to 
expand. It is all mutual (Interview Dr. DS, November 28, 2013). 
Collaborative networks with such hospitals provide a pool of specialist physicians who can 
recruit patients to their clinics. IJRM’s web page mentions only a few of such collaborations 
and describes therapeutic support other than stem cells, such as immunotherapy for cancer. It 
asks potential clients to send email enquiries about specific stem cell treatment centers. Mr. 
SR, who is presently working as the Marketing Head at Lifelong Hospital, a former 
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collaborating partner of IJRM (2006 -08) and provider of adult autologous stem cell therapy 
for several disease conditions including spinal cord injury, reflected on IJRM’s networks: 
There is a Japanese mind behind what you see at IJRM. Without Japanese 
investment and advanced technology, it cannot do anything - Just imagine the 
situation where you have links with 60 70 hospitals across the region and you 
get at least 3 or 4 patients from each hospital every year. It is a huge number. 
You give incentives to the doctor or clinic that introduces a patient to you or 
you charge than for providing stem cell processing and expansion services. 
You know how expensive these services are. And very intelligently Dr. SA 
has combined immunotherapy with stem cell treatment services. It highlights 
the collaborations that it has with institutes in Canada and Japan. It also boasts 
its links with universities outside Chennai. This is a very good business model 
(Interview, Mr. SR, Business Head, Lifelong Hospital, Chennai, November 30, 
2013). 
A Chennai-based clinician, who regularly works with IJRM in providing autologous stem cell 
therapy for critical limb ischemia, spinal cord injury, and ischemic heart disease, viewed the 
collaboration as a mutually beneficial exercise: 
Ours is a small, specialized facility, but we are very proud to be working 
closely with IJRM. They have all the modern technological facilities from 
Japan, which would be otherwise difficult for us to get here. It is resource-
intensive. But they also benefit from easy patient access, from the medical 
data that is generated through these therapies. The patients get an alternative 
therapy without which their life conditions would have been very different. I 
think it’s a win-win situation for all (Interview, Dr. PA, Chennai, November 
30, 2013) 
The interviews show actor assessment of their collaborative partners and the rationale behind 
their motivation to join the network. Their assessments evaluate geographical spaces 





We now have come to the point at which we can explain how stem cell experimentation and 
treatment continue to thrive in India despite the introduction of relatively stringent guidelines 
for stem cell research in December 2013. In this article, we have deliberated on the 
developmental history of the making and remaking of guidelines, the shift in treatment 
provision – from institutional embedment to collaborative networks, and strategic linking and 
exposure in collaborative network.  Several issues that emerged need to be highlighted. 
First, the IC-SCR and NAC-SCRT are not functioning: the ICMR-DBT (2007) guidelines 
stated that:  
 
All stem cell therapy other than BMT (for accepted indications) shall be treated as 
experimental. It should be conducted only as clinical trial after approval of the IC-
SCRT/IEC and DCGI (for marketable products). All experimental trials shall be 
registered with the NAC-SCRT (ICMR -DBT 2007, pp. 11 -12).  
 
Many practitioners still continue to provide clinical interventions by taking the term ‘treated 
as experimental’ to be a tacit endorsement for practicing and promoting unproven stem cell 
therapy. The revised guidelines (2013) state that:  
Clinical trials using cells derived from the differentiation of human ES or iPS cells, or 
any stem cell after major manipulation (as defined under Clause 6.1.6.3) shall require 
approval of the DCGI after obtaining approval from National Apex Committee for 
Stem Cell Research and Therapy (NAC-SCRT) through Institutional Committee for 
Stem Cell Research (IC-SCR) and Institutional Ethics Committee (IEC) (ICMR-DBT 
2013, pp.9).  
 
Some providers nevertheless refer to the Helsinki Declaration that places emphasis on the 
‘physician’s judgment’ and compassionate ground (WMA 2008; Chen et al. 2014). The main 
issue is that the NAC-SCRT and IEC committees ‘either do not exist’ or are ‘not in 
operation’, as a provider (TP-3) emphasized, where he said;- 
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The guidelines talk about so many things. They have been saying this for so 
many years. Can you ask them where is their committee, where are their 
members, why do they sit on the applications we send and take no action. Bet 
me either they do not exist or they are not in operation. 
This criticism suggests that there is institutional incompetency regarding the organizational 
capacity of the regulatory agencies, calling into question the reliability of the regulators.  
Second, as highlighted by Tiwari & Raman (2014), there is an issue of ambiguity as to which 
agency to approach in cases of medical malpractice, patient safety, forgery, false claims and 
the ethical conduct of clinical trials. It is important to mention that neither the ICMR nor the 
DBT has a legislative remit over medical research. The Drug Controller General India 
(DCGI) under the gamut of Central Drug Standard Organization (CDSCO), which is 
responsible for regulatory control over the import of drugs, the approval of new drugs and 
clinical trials, does not have sufficient expert capacity to evaluate stem cell proposals. The 
Medical Council of India (MCI) only has statutory authority to deregister a practitioner. In 
this regard, a policy maker (PM-2) suggested that, “in extreme circumstances, in case of any 
harm to a patient or in case of medical malpractice, the patient needs to lodge a complaint” 
(personal interview, 11.5.2014). But in case of clandestine stem cell enterprises, patients are 
not in a position to lodge a complaint.  
Third, the guidelines are not legally enforceable: An important development took place when 
the Ministry of Health and Family Welfare established a high-powered committee in June 
2013 to suggest a road map for the regulation of stem cell- and other cell-based therapies 
practiced in India. The committee drafted the Guidance Document for Regulatory Approvals 
of Stem Cells and Cell based Products (SCCP) in December 2013. The Document is now 
available in the public domain and is open for public discussion. The rules and regulations in 
this Guidance Document apply to all organizations such as hospitals, private clinics, institutes, 
universities, tissue banks, and companies that wish to obtain a license for the use of SCCPs 
for therapeutic purposes in India. Failure to comply with the conditions of this document or 
using SCCPs without a CDSCO/DCG (I) license is penalized in agreement with the Drugs 
and Cosmetics Rules (CDSCO 2013). But until parliament promulgates an appropriate Act 
(hard law) enforcement with legal authority remains problematic. From the mid-2000s 
onwards, social-science studies as well as Indian stem cell observers have argued that the 
governance vacuum in India was a result of the lack of statutory regulation of stem cell 
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activities (Salter 2008, Patra & Sleeboom-Faulkner 2011, Tiwari and Raman 2014). The 
statutory gap in Indian stem cell governance was addressed with changes announced in 2014 
to the DCGI’s legal remit and a revised set of guidelines produced by the ICMR-DBT 
guidelines. However, doubts still remain not only about the enactment of the new law-in-
practice but also about the blurred difference between guidelines and regulations that prevails 
in the field of stem cell research and therapy in India. The ICMR-DBT stem cell research 
guidelines mainly seem to assist with providing ways of complying with the legislations. 
Fourth, the complexity of the collaborative-network structure makes it easy to circumvent the 
regulation. As clearly demonstrated through the case study of IJRM, the complex 
collaborative network structure emerging through the ‘hub-spoke’ kind of reciprocal 
relationships makes it difficult to monitor or regulate the field; most of actors and 
practitioners involved are not registered to any agency. As elaborated in earlier section, 
IJRM’s central position and the vertical and horizontal network relationship with actor-
stakeholders has important impact on the flow of resources in terms of knowledge, capacity, 
technology and resources. These networks are based on strategic linking and scaling tactics 
with three well-crafted components: one, strategic linking through goal-setting, where the 
‘hub’ mobilizes and steers the expertise and talents of participating actors to achieve specific 
goals; two, strategic exposure, whereby certain aspects of collaborative network activities are 
exposed more than others; and, three, the strategic linking of geographical spaces, whereby 
actors negotiate scaled spaces at a local, national and global levels. The multiplicity of actors 
involved, the complexities of their relative importance to the network and diversities of their 
locations is an indication that this collaborative network-structure will not only survive and 
thrive but can skillfully circumvent the regulatory provisions, which in India, as of now, is 
designed to comply with guidelines.  
Fifth, there are alternative cell therapies available that provides safe coverage to unproven 
stem cell treatments. As a result of the 2013 regulation, companies have started to emphasize 
the provision of ‘alternative cell therapies’ over ‘stem cell therapy,’ which have not 
undergone clinical trials either. For instance, IJRM claimed that “more than 23 types of 
cancer have been treated using AIET without any adverse reactions and there are hundreds of 
clinical studies” (IJRM webpage 2014). It claims that the Bioteknika Institute in Japan 
(pseudonym) had started AIET in the year 2000 and has provided treatment to more than 
10,000 patients to date with no adverse reactions, as with other conventional treatments 
(IJRM webpage 2014). Further, clinical stem cell intervention is made available through the 
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approved randomized clinical trials route when in collaboration with a foreign company. Dr. 
Bhaskar, Clinical Manager of a multinational clinical research organization (CRO) based in 
Bangalore, explained that: 
There are many stem cell companies, both from India and abroad for whom 
our CRO is carrying out clinical trials, especially for mesenchymal stem cell-
based products and autologous SCT-based indications. There are around 5 or 6 
disease conditions for which they recruit 20 to 50 patients each per study. 
These studies are multi-centric and our CRO has networks across several 
states in India to provide the required number of patients and volunteers as per 
the required exclusion-inclusion criteria (Interview, Bhaskar, 03.06.2014). 
With the increasing number of companies and institutes investing in stem cell research and 
product development for an increasing number of indications for clinical trials, there is scope 
for wide recruitment. Apart from the instances of these two sets of provision of alternative 
therapies i.e. AIET and randomized clinical trials, other services, such as tertiary care under 
medical tourism, especially to offshore patients, also provide safe coverage of unproven stem 
cell. Medical travel to corporate hospitals in India takes place for an array of medical 
conditions such as kidney transplantation, assisted reproductive technologies, and cardiac 
surgery. These travels are driven by patients who aim to avoid treatment delays, and to obtain 
relatively affordable access to healthcare (Turner 2007). Corporate hospitals that provide 
tertiary care have skillfully tapped into pools of foreign patients, non-resident Indian patients 
and wealthy Indian patients for experimental stem cell therapy. Many of them have combined 
stem cell therapy provisions as an auxiliary unit to their super-specialty healthcare service 
platter. A physician who was earlier associated with IJRM and now is in-charge of stem cell 
facility at the Globus Hospital (pseudonym) in Chennai said the following about how stem 
cell therapy is offered as a coverage; 
 We are a super-specialty corporate hospital. We need to very well understand the 
 health needs of the high-end patients that come to us for treatment for different kinds 
 of disease profiles. We decided to keep stem cell therapy as a service in our service 
 platter. Initially, it was not our main focus. But, now patients visiting for treatment of 
 a particular condition may like to use stem cell as an option.... treatment of peptic foot 
 ulcer is one condition that we are good at. 
With the burgeoning growth of corporate hospitals in metro cities in India, such practices 
either alongside alternative therapy or as an additional therapy, the provision of experimental 





In this article we have illustrated how within a decade the organization of clinical stem cell 
interventions in India has been altered from being embedded in specific private, public, or 
independent institutions to being provided through complex entrepreneurial networks.  The 
latter involves strategic linkage created by entrepreneurs with global technology and 
managerial skills of public and private organizations, including universities, hospitals, high-
tech companies, and other companies. This organizational trend was brought about by 
national-level attempts to regulate stem cell therapy and research, government policy of 
investment into the formation of public -private partnerships, and by developments in 
science itself that required an increasing variety of scarce material and intellectual resources. 
Using the example of IJRM, we illustrated the ways in which a distinct transnational network 
employs forms of strategic linking to pursue business success by means of their relative 
centrality in stem cell networks. And, finally, we showed how the provision of clinical stem 
cell intervention has continued despite the ‘thicker’ regulatory measures of December 2013. 
We found that it is actually the increasing complexity of the regulation, and a lack of 
resources to implement them, in combination with an organizational increase in complexity 
in the provision of clinical interventions that have enabled this continuation. We conclude 
that, rather than good ethical practice or scientific proof, in practice, it is the institutional 
sophistication and available regulatory mechanisms and resources that condition the ways in 
which industry caters for patient demand for USCT. The extent to which this is or is not in 
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